IL145503A - Surfactant-lipase complex immobilized on insoluble matrix - Google Patents
Surfactant-lipase complex immobilized on insoluble matrixInfo
- Publication number
- IL145503A IL145503A IL145503A IL14550301A IL145503A IL 145503 A IL145503 A IL 145503A IL 145503 A IL145503 A IL 145503A IL 14550301 A IL14550301 A IL 14550301A IL 145503 A IL145503 A IL 145503A
- Authority
- IL
- Israel
- Prior art keywords
- lipase
- surfactant
- group
- immobilized
- preparation
- Prior art date
Links
- 239000004367 Lipase Substances 0.000 title claims description 336
- 239000011159 matrix material Substances 0.000 title claims description 76
- 102000004882 Lipase Human genes 0.000 claims description 329
- 108090001060 Lipase Proteins 0.000 claims description 329
- 235000019421 lipase Nutrition 0.000 claims description 328
- 229940040461 lipase Drugs 0.000 claims description 295
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 134
- 239000004094 surface-active agent Substances 0.000 claims description 114
- 238000000034 method Methods 0.000 claims description 89
- 102000004190 Enzymes Human genes 0.000 claims description 85
- 108090000790 Enzymes Proteins 0.000 claims description 85
- 229940088598 enzyme Drugs 0.000 claims description 78
- 238000002360 preparation method Methods 0.000 claims description 63
- 238000006243 chemical reaction Methods 0.000 claims description 55
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 55
- 239000000194 fatty acid Substances 0.000 claims description 55
- 229930195729 fatty acid Natural products 0.000 claims description 55
- 150000004665 fatty acids Chemical class 0.000 claims description 52
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 42
- 238000009884 interesterification Methods 0.000 claims description 41
- 238000005886 esterification reaction Methods 0.000 claims description 39
- 239000003921 oil Substances 0.000 claims description 36
- 235000019198 oils Nutrition 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 33
- 150000003626 triacylglycerols Chemical class 0.000 claims description 33
- 238000006136 alcoholysis reaction Methods 0.000 claims description 30
- 230000032050 esterification Effects 0.000 claims description 30
- 239000000758 substrate Substances 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 27
- 238000005809 transesterification reaction Methods 0.000 claims description 27
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 27
- 239000003960 organic solvent Substances 0.000 claims description 26
- 229920001429 chelating resin Polymers 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229930006000 Sucrose Natural products 0.000 claims description 18
- 239000005720 sucrose Substances 0.000 claims description 18
- 239000004006 olive oil Substances 0.000 claims description 16
- 235000008390 olive oil Nutrition 0.000 claims description 16
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 15
- 239000003456 ion exchange resin Substances 0.000 claims description 15
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 15
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 14
- 235000021355 Stearic acid Nutrition 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 12
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 12
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 12
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- 239000005909 Kieselgur Substances 0.000 claims description 10
- 240000005384 Rhizopus oryzae Species 0.000 claims description 10
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 241001661345 Moesziomyces antarcticus Species 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000008117 stearic acid Substances 0.000 claims description 9
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000012736 aqueous medium Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims description 7
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 7
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 7
- 150000002191 fatty alcohols Chemical class 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 6
- 235000014593 oils and fats Nutrition 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 241000228245 Aspergillus niger Species 0.000 claims description 5
- 241001508395 Burkholderia sp. Species 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 241001373560 Humicola sp. Species 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 241000498617 Mucor javanicus Species 0.000 claims description 5
- 235000019482 Palm oil Nutrition 0.000 claims description 5
- 241000589516 Pseudomonas Species 0.000 claims description 5
- 241000235403 Rhizomucor miehei Species 0.000 claims description 5
- 241000235527 Rhizopus Species 0.000 claims description 5
- 235000013752 Rhizopus oryzae Nutrition 0.000 claims description 5
- 241000952054 Rhizopus sp. Species 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 239000003610 charcoal Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000002540 palm oil Substances 0.000 claims description 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- 241000222175 Diutina rugosa Species 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 241000589774 Pseudomonas sp. Species 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 235000021342 arachidonic acid Nutrition 0.000 claims description 4
- 229940114079 arachidonic acid Drugs 0.000 claims description 4
- 239000000828 canola oil Substances 0.000 claims description 4
- 235000019519 canola oil Nutrition 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 235000019879 cocoa butter substitute Nutrition 0.000 claims description 4
- 235000005687 corn oil Nutrition 0.000 claims description 4
- 239000002285 corn oil Substances 0.000 claims description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 235000020256 human milk Nutrition 0.000 claims description 4
- 210000004251 human milk Anatomy 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 244000090896 Nigella sativa Species 0.000 claims description 3
- 235000016698 Nigella sativa Nutrition 0.000 claims description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229960004232 linoleic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000001711 nigella sativa Substances 0.000 claims description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 3
- 229960002969 oleic acid Drugs 0.000 claims description 3
- 229940098695 palmitic acid Drugs 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 3
- 229960004274 stearic acid Drugs 0.000 claims description 3
- 108050006759 Pancreatic lipases Proteins 0.000 claims description 2
- 102000019280 Pancreatic lipases Human genes 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 229940116369 pancreatic lipase Drugs 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 103
- 235000011076 sorbitan monostearate Nutrition 0.000 description 103
- 239000001587 sorbitan monostearate Substances 0.000 description 103
- 229940035048 sorbitan monostearate Drugs 0.000 description 103
- 102000004169 proteins and genes Human genes 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 52
- 230000000694 effects Effects 0.000 description 49
- -1 sodium alkoxide Chemical class 0.000 description 26
- 229920002472 Starch Polymers 0.000 description 21
- 239000008107 starch Substances 0.000 description 21
- 235000019698 starch Nutrition 0.000 description 21
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 20
- 108010093096 Immobilized Enzymes Proteins 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- 229960001947 tripalmitin Drugs 0.000 description 11
- 239000003925 fat Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229920000084 Gum arabic Polymers 0.000 description 8
- 235000010489 acacia gum Nutrition 0.000 description 8
- 239000000205 acacia gum Substances 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 244000215068 Acacia senegal Species 0.000 description 7
- 239000001856 Ethyl cellulose Substances 0.000 description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 7
- 239000011942 biocatalyst Substances 0.000 description 7
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 7
- 235000019325 ethyl cellulose Nutrition 0.000 description 7
- 229920001249 ethyl cellulose Polymers 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 102000015439 Phospholipases Human genes 0.000 description 6
- 108010064785 Phospholipases Proteins 0.000 description 6
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 230000009144 enzymatic modification Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000011078 sorbitan tristearate Nutrition 0.000 description 6
- 239000001589 sorbitan tristearate Substances 0.000 description 6
- 229960004129 sorbitan tristearate Drugs 0.000 description 6
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 5
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 5
- 239000004164 Wax ester Substances 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229940035044 sorbitan monolaurate Drugs 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 235000019386 wax ester Nutrition 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004147 Sorbitan trioleate Substances 0.000 description 4
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000019337 sorbitan trioleate Nutrition 0.000 description 4
- 229960000391 sorbitan trioleate Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 2
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940079919 digestives enzyme preparation Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000003248 enzyme activator Substances 0.000 description 2
- 125000001924 fatty-acyl group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710098556 Lipase A Proteins 0.000 description 1
- 101710099648 Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000009885 chemical interesterification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000009886 enzymatic interesterification Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000002316 solid fats Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
- C12N11/087—Acrylic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6454—Glycerides by esterification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6458—Glycerides by transesterification, e.g. interesterification, ester interchange, alcoholysis or acidolysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Enzymes And Modification Thereof (AREA)
- Fats And Perfumes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
5229B/np2/98 Πυ?ϋΤ] ^"73 Π-ΠϋΤΙ *7D UlUT-il ΠΰΙϋ "7^9 -ΙΙΠΤΗΚΕΓ'7 *71D Dp"73mp SURFACTANT-LIPASE COMPLEX IMMOBILIZED ON INSOLUBLE MATRIX SURFACTANT-LIP ASE COMPLEX IMMOBILIZED ON INSOLUBLE MATRIX Field of the Invention The present invention relates to an insoluble matrix immobilized surfactant-coated hpase complex, to a method of preparing same and to the use of same as a biocatalyst for catalyzing, for example, inter- and/or trans-esterification of oils and fats in hydrophobic organic media. The novel procedures include two steps. In the first step, the enzyme is activated by being coated with a surfactant. In the second step, the enzyme is immobilized on the matrix of choice. These steps can be executed in any order.
Background of the Invention Enzymatic modification of the structure and composition of oils and fats is of great industrial and clinical interest. This process is accomplished by exploiting regio-specific lipases in inter-esterification and/or trans-esterification reactions utilizing fats or oils as substrates (Macrea, A.R., 1983, J. Am. Oil Chem. Soc. 60: 291-294).
Using an enzymatic process, it is possible to incorporate a desired fatty acyl group on a specific position of a iriacylglycerol molecule, whereas conventional chemical inter-esterification does not possess regio-specificity. 9 Conventionally, chemical reactions are promoted by sodium metal, sodium alkoxide or cobalt chloride that catalyze acyl migration among triglyceride molecules, leading to the production of triglycerides possessing randomly distributed fatty acyl residues (Erdem-Senatalar, A., Erencek, E. and Erciyes, A.T., 1995, J. Am. Oil Chem. Soc. 72: 891-894).
In recent years, a number of studies have demonstrated the potential application of lipases as promising biocatalysts for different esterification reactions in organic media (Wisdom, R.A., Dunhill, P., and Lilly, M.D., 1987, Biotechnol. Bioeng. 29: 1081-1085).
Lipases with 1,3-positional specificity principally catalyze hydrolysis of fats and oils, to yield free fatty acids and glycerol. However, recent studies have shown that lipases with 1,3-positional specificity are also capable of catalyzing two types of esterification reaction in microaqueous organic media (Quinlan, P. & Moore, S., 1993, INFORM 4: 580-585). The first of these reactions is an inter-esterification or acidolysis reaction in which free fatty acids react with different triglycerides to yield new triglyceride molecules. The second type of reaction is trans-esterification in which two different triglyceride molecules react to give new triglyceride molecules (see Figures la-b). In both of these enzymatic reactions, the sn-2 position of the reacting triglycerides remains unchanged.
In general, water concentration plays an important role in determining the activity of enzymes. It also affects the equilibrium state of the reactions performed in hydrophobic organic solvents (Valiverty, E.H., Hailing, P.J. and Macrae, A.R., 1993, Biotechnol. Lett. 15: 1133-1138). Since water is vital for the activity of enzymes in both hydrolysis as well as in synthesis reactions, as a compromise between hydrolysis and synthesis of triglycerides, the concentration of water is lowered so that the occurrence of undesirable reactions is minimized, but the water available is sufficient, for the- enzyme to remain active.
At high concentrations of water, e.g., above 5 % of solvent weight, lipases possess preferably their natural hydrolytic activity, therefore, hydrolysis reaction proceeds. However, at low concentrations of water, e.g., below 1 % of solvent weight, lipases catalyze the reverse reaction, that is, synthesis.
A typical range of water concentrations needed for promotion of inter-esterification reaction between different oils in organic media is 1- 10 weight percent (wt %) of the hydrophobic organic solvent. This water concentration can normally facilitate also the hydrolysis reaction thus producing undesirable partial glycerides (mono- and di-glycerides) in the range of 10-20 wt % of the initial triglycerides concentration, as byproducts.
The scope for exploiting the positional specificity of lipases, especially, in the food and oleochemical industries for the production of high-valued special fats is enormous. For example, cocoa butter substitute, simulated human milk fat and other structured triglycerides of specific nutritional quality can be obtained' enzymatically by employing lipases with 1,3-positional specificity (Vulfson, E.N., 1993, Trends Food Sci. Technol. 4: 209-215).
In view of the foregoing, it is recognized that there is a need to develop new structured triglycerides with both medium-chain and a- 3 polyunsaturated fatty acids that would be devoid of the adverse effects of the naturally occurring -3 polyunsaturated fatty acids, or saturated fatty acids. For example, molecules of MCTs having one of their acyl groups substituted with an essential long-chain fatty acid would provide the nutritional advantages of both MCTs and LCTs. This approach is illustrated by the very useful triglyceride that is formed by incorporating the acyl form of the polyunsaturated fatty acids, EPA, DHA or o-linolenic acid at the Sn-2 position of a triglyceride molecule having a medium-chain fatty acyl group at the sn-1 and s/i-3 positions (Odle, J. , 1997, J. Nutr. 127: 1061).
The aforementioned polyunsaturated fatty acids incorporated into triglyceride molecules were shown to have several health benefits with respect to cardiovascular disease, immune disorders and inflammation, allergies, diabetes, kidney diseases, depression, brain development and cancer. Furthermore, medium-chain fatty acids incorporated into the same triglyceride molecule are of major importance in some clinical uses, especially, for facilitating absorbability and solubilization of cholesterol in blood serum, and for providing readily available energy- sources for body consumption.
Many different approaches for the use of lipases in organic media have been attempted in order to activate them and to improve their performance. These include the use of lipase powder suspended in either microaqueous organic solvents or in biphasic systems, and native lipases adsorbed on microporous matrices in fixed- and fluidized-bed reactors (Malcata, et ai, 1990, J. Am. Oil Chem. Soc. 890-910). Furthermore, lipases have been hosted in reverse micelles, and in some studies lipases were attached to polyethylene glycol or hydrophobic residues to increase their solubility and dispersibility in organic solvents.
None of the abovementioned approaches was found to be applicable for all enzymatic systems. However, in many cases, when lipases were treated in one way or another as described, their performance with respect to activity, specificity, stability and dispersibility in hydrophobic organic systems was improved.
In recent studies, the development of surfactant-coated lipase preparations has been reported (e.g., Basheer. S., Mogi, K. and Nakajima. M.. 1995, Biotechnol. Bioeng. 45: 187-195). This enzyme modification converts slightly active or completely inactive lipases, with respect to esterification of triglycerides and fatty acids in organic media, into highly active biocatalysts. The newly developed surfactant-lipase complexes have been further studied and used for the inter- esterification reaction in organic solvent systems to produce structured triglycerides of major importance in medical applications (Tanaka, Y., Hirano, J. and Funada, T., 1994, J. Am. Oil Chem. Soc. 71: 331-334).
In another approach to the problem, various immobilized-enzyme reactor systems were used in lipase-catalyzed reactions in microaqueous hydrophobic organic media (e.g., Basheer, S., Mogi, K., Nakajima, M., 1995, Process. Biochemistry 30: 531-536). These included fixed- and fluidized-bed reactors, and a slurry reactor. In the published studies, lipase immobilized onto an inorganic matrix was used both in a batch reactor system, and in fixed-bed bioreactor systems. However, the lipases employed were not surfactant-coated and therefore have the same limitations as free lipase systems. These limitations include: 1. Difficulties in recovering the enzyme after completion of the process; 2. Rapid loss of activity of the free enzyme in the reaction medium; 3. Problems of recoverability of expensive enzymes; . Low synthetic activity of free lipases in organic solvents.
Neither of the abovementioned strategies has satisfactorily solved the technical problems encountered in directing trans- and inter-esterification of fats and oils. It is therefore an object of the invention to provide a lipase preparation that is capable of catalyzing esterification reactions in fats and oils with a much greater efficacy than existing methods.
It is another purpose of the invention to provide a lipase preparation that incorporates both immobilization to a matrix, and treatment by coating with a surfactant.
It is a further object of the invention to provide such a lipase preparation that may be used repeatedly, on an industrial scale with minimal loss of activity.
It is a further object of the invention to provide a method for preparing said insoluble matrix -immobilized, surfactant-coated lipase complex.
Yet a further purpose of the invention is to provide a process for preparing structured triacyl glycerols, using said insoluble matrix-immobilized, surfactant-coated lipase complexes.
Other objects and advantages of the invention will become apparent as the description proceeds.
Summary of the Invention It has now been surprisingly found, and this is an object of the invention, that the dual modification of crude lipase by (1) coating with a surfactant, and (2) immobilization to an insoluble matrix; results in a synergistic improvement in the efficiency of the enzyme to catalyze trans- and inter-esterification reactions, when compared to either of these two treatments alone. It has been further unexpectedly found that it is possible to enhance the catalytic stabihty of said dually modified lipase for esterification reactions, by providing the enzyme preparation in a granulated form.
The invention is primarily directed to a lipase preparation comprising an insoluble matrix and a surfactant-coated lipase complex immobilized onto said insoluble matrix.
The immobilization of the lipase complex onto the insoluble matrix may be achieved by several different methods. According to a preferred embodiment of the invention, however, the surfactant-coated lipase complex is covalently, io ically or physically bound to the insoluble matrix.
The invention encompasses the use of many types of matrix, said matrices being selected from the group consisting of an inorganic insoluble matrix and an organic insoluble matrix.
In a preferred embodiment of the invention, the inorganic insoluble matrix is selected from the group consisting of alumina, diatomaceous earth, Celite, calcium carbonate, calcium sulfate, ion-exchange resin, silica gel and charcoal. The abovementioned ion-exchange resin may be of any suitable material, but in a preferred embodiment is selected from the group consisting of Amberlite and Dowex.
Although any suitable organic insoluble matrix may be use, in a preferred embodiment of the invention, the organic insoluble matrix is selected from the group consisting of Eupergit, ethylsulfoxycellulose and aluminium stearate.
In a preferred embodiment, the content of the lipase is 2-20 weight percent of the surfactant-coated lipase complex. In a still more preferred embodiment, the content of the lipase is 0.01-1.0 weight percent of the preparation.
The invention provides the above-described lipase preparation, wherein the surfactant in the surfactant-coated lipase complex includes a fatty acid conjugated to a hydrophilic moiety. In a preferred embodiment, the fatty acid is selected from the group consisting of monolaurate, monomyristate, monopalmitate, monostearate, dilaurate, dimyristate, dipalmitate, distearate, trilaurate, trimynstate, tripalmitate and tristearate. In a preferred embodiment, the hydrophilic moiety is selected from the group consisting of a sugar, a phosphate group, a carboxylic group and a hydroxylated organic residue. In a more preferred embodiment, the sugar is selected from the group consisting of sorbitol, sucrose, glucose and lactose. Although the fatty acid and the hydrophilic moiety may be linked by any suitable type of bond, in a preferred embodiment, the fatty acid and the hydrophilic moiety are conjugated via an ester bond.
Although the lipase may be derived or obtained from any convenient source, in a preferred embodiment, the lipase is derived from a microorganism. Many different species of both microorganisms and multicellular organisms may be used as a source of lipase for the lipase preparation of the invention. The invention, however, is particularly directed to the use of lipase that is derived from a species selected from the group consisting of Burkholderia sp., Candida antraciica B, Candida rugosa, Pseudomonas sp., Candida antractica A, Porcine pancreas lipase, Humicola sp., Mucor miehei, Rhizopus javan., Pseudomonas fluor., Candida cylindrcae, Aspergillus niger, Rhizopus oryzae, Mucor javanicus, Rhizopus sp., Rhizopus japonicus and Candida antractica.
In a further aspect, the invention is directed to a lipase preparation comprising an insoluble matrix and a surfactant-coated lipase complex immobilized onto said insoluble matrix, said lipase preparation being provided in an organic solvent. In a preferred embodiment, the organic solvent is selected from the group consisting of n-hexane. toluene, iso-octane. n -octane, benzene, cyclohexane and di-iso-propylether. The invention is further directed to the use of said lipase preparation as a catalyst for esterification, mter-esterification and trans-esterification of oils and fats and alcoholysis of triglycerols and fatty alcohols. In a preferred embodiment, the lipase preparation is used as a catalyst with 1,3-positional specificity with respect to triacylglycerols.
In another aspect, the invention is directed to a lipase preparation as described above, wherein said preparation is in granulated form.
The invention also provides a lipase preparation, as described hereinabove, wherein the insoluble matrix has been modified with a fatty acid derivative.
In a further aspect the invention is directed to an enzyme preparation, as described hereinabove, for use in a reaction environment without the need for water addition.
The invention also encompasses a method for improving the stability of a surfactant-coated immobilized lipase complex, comprising granulating same prior to contacting it with the substrate to be reacted.
In a further aspect, the invention provides a method of preparing an insoluble matrix-immobilized surfactant-coated lipase complex comprising, in any desired order, the steps of: (a) contacting a lipase in an aqueous medium with a surfactant, at a concentration and temperature, and for a period of time sufficient to obtain a coating of said hpase; and (b) contacting said lipase in an aqueous medium, with an insoluble matrix, at a concentration, under conditions and for a period of time sufficient to obtain immobilization of said hpase on said matrix.
In a preferred embodiment of the abovementioned method, the lipase is first contacted with the insoluble matrix, and thereafter with the surfactant. In another preferred embodiment thereof, the lipase is first contacted with the surfactant, and thereafter with the insoluble matrix.
In a preferred embodiment of the invention, the above-described method further comprises the separation of the matrix-immobilized surfactant-coated hpase complex from the aqueous solution in which it was formed. In a still more preferred embodiment, this method also further comprises the step of drying said matrix-immobilized surfactant-coated lipase complex. Although the drying step may be accomplished by any convenient method, in a preferred embodiment, said drying is effected by freeze drying. In another preferred embodiment, the matrix-immobilized surfactant-coated lipase complex is dried to a water content of less than 100 parts per million by weight.
In another preferred embodiment, the aqueous solution used in the above-described method is a buffered-aqueous solution.
In yet another preferred embodiment of the above-described method, the lipase and surfactant are contacted in the aqueous medium by: (i) dissolving said surfactant in an organic solvent for obtaining a dissolved surfactant solution; and (ii) mixing said lipase and said dissolved surfactant solution in said aqueous medium.
In another preferred embodiment, the method further comprises sonication of the aqueous solution.
In yet another preferred embodiment of the method of the invention, the insoluble matrix is selected from the group consisting of alumina, diatomaceous earth, Celite, calcium carbonate, calcium sulfate, ion-exchange resin, silica gel, charcoal, Eupergit, ethylsulfoxycellulose, aluminium stearate and fatty acid derivative-treated Celite or other inorganic matrices.
In another preferred embodiment, the surfactant of the method includes a fatty acid conjugated to a hydrophilic moiety. In a still more preferred embodiment, said fatty acid is selected from the group consisting of monolaurate, monomyristate, monopalmitate. monostearate. dilaurate, dimyristate, drpalmitate, distearate, trilaurate, trimyristate, tripalmitate and tristearate.
In another preferred embodiment of the method of the invention, the hydrophilic moiety is selected from the group consisting of a sugar and a phosphate group and a carboxylic group and a polyhydroxylated organic residue. In a still more preferred. embodiment, the sugar is selected from the group consisting of sorbitol, sucrose, glucose and lactose.
In another preferred embodiment of the method of the invention, the fatty acid and the hydrophilic moiety are conjugated via an ester bond.
In a preferred embodiment of the method of the invention, the lipase is derived from an organism. In a more preferred embodiment, the lipase is derived from a multicellular microorganism. Although the lipase may be derived from any suitable host, in a preferred embodiment, the lipase is derived from a species selected from the group consisting of Burkholderia sp., Candida antarctica B, Candida r gosa, Pse domonas sp., Candida antractica A, Porcine pancreatic lipase, Humicola sp., Mucor miehei, Rhizopus javan., Pseudomonas fluor., Candida cylindrcae, Aspergillus niger, Rhizopus oryzae, Mucor javanicus. Rhizopus sp... Rhizopus japonicus and Candida antarctica.
In another aspect, the invention is directed to a process for preparing structured triacylglycerols by estenfication, acidolysis, trans-esterification, mter-esterification or alcoholysis between two substrates comprising contacting an insoluble matrix-immobilized surfactant-coated lipase complex with said substrates.
In a preferred embodiment of this process, the matrix-immobilized surfactant-coated lipase , complex is contacted with the substrates in the presence of an organic solvent.
In another preferred embodiment of this process, at least one of the substrates is selected from the group consisting of an oil, a fatty acid, a triacylglycerol and a fatty alcohol. Although many different types of oil may be used in this process, in a preferred embodiment, the oil is selected from the group consisting of olive oil, soybean oil, peanut oil, fish oil, palm oil, cotton seeds oil, sunflower oil, Nigella sativa oil, canola oil and corn oil. In another preferred embodiment, the fatty acid is selected from the group consisting of medium and short-chain fatty acids and their ester derivatives. In a still more preferred embodiment, the fatty acid is selected from the group consisting of oleic acid, palmitic acid, linolic acid, linolenic acid, stearic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and their ester derivatives.
While the above-described process may be performed in any suitable receptacle, said process, in a preferred embodiment, is carried out in a tank reactor or in a fixed-bed reactor.
The invention also encompasses a triacylglycerol prepared according to the above-described process for use as a cocoa butter substitute, human milk fat-like triglycerides for special diets, or structured triglycerides for medical applications.
Brief Description of the Drawings The invention herein described, by way of example only, with reference to the accompanying drawings, wherein: FIG. la presents an inter-esterification acidolysis reaction catalyzed by lipase with 1,3 -positional specificity. P represents glycerol bound palmitic acid, C represents glycerol bound capric acid. PA and CA represent free palmitic and capric acids, respectively.
FIG. lb presents a trans-esterification reaction catalyzed by lipase with 1,3-positional specificity. P represents glycerol bound palmitic acid and C represents glycerol bound capric acid.
FIG. 2 depicts the chemistry associated with covalent immobilization of lipase to Eupergit C 250L followed by coating the covalently immobilized enzyme with a surfactant.
FIG. 3 presents inter-esterification reaction profiles of physically immobilized lipases. Reaction conditions were 50 mg tripalmitin, 35 mg capric acid and 20 mg' surfactant-coated lipase (Saiken 100 - triangles, or Lilipase A10-FG - squares) immobilized on DE in 10 ml n-hexane. The reaction system was magnetically stirred and thermostated at 40 °C.
FIG. 4 presents an Arrhenius plot for the inter-esterification reaction of tripalmitin and capric acid with DE-physically immobilized surfactant-coated Lilipase A 10-FG.
FIG. 5 is a bar graph showing the functional stability of Lilipase A 10FG immobilized on Celite and granulated with 2 % starch.
FIG. 6 is a bar graph showing the functional stability of powdered Lilipase A 10FG modified with sorbitan monostearate and immobilized on Celite.
FIG. 7 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan monostearate, immobilized on Celite and granulated with 2 % starch.
FIG. 8 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan monostearate, immobilized on Celite and granulated with ethyl cellulose.
FIG. 9 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan monostearate, immobilized on Celite and granulated with 2 % gum Arabic.
IS FIG. 10 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan monostearate, immobilized on Amberlite IRA-900 and granulated with ethyl cellulose.
FIG. 11 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan monostearate, immobilized on Celite and granulated with 2 % agarose.
FIG. 12 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan monostearate, immobilized on Celite and granulated with 4 % starch.
FIG. 13 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan tristearate, immobilized on Celite and granulated with 2 % starch.
FIG. 14 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan monostearate, immobilized on aluminium monostearate and granulated with 2 % starch. The graph also shows comparable results for unmodified enzyme, immobilized on aluminium monostearate and granulated with 2 % starch.
FIG. 15 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan monostearate, immobilized on Amberlite XAD-16 and granulated with 2 % starch.
FIG. 16 is a bar graph showing the functional stability of Lilipase A 10FG modified with sorbitan monostearate, immobilized on Amberlite XAD-7 and granulated with 2 % starch.
Detailed Description of Preferred Embodiments The present invention relates to a surfactant-coated lipase or phospholipase complex immobilized on an organic or inorganic insoluble matrix (e.g., particulate solid support) which can be used to catalyze inter and trans-esterification reactions, particularly of oils and fats and alcoholysis of fatty- alcohols. The invention also makes provision for preparing the enzyme preparation in a granulated form that demonstrates increased stability of activity. Specifically, the present invention can be used for preparing structured triacylglycerols possessing desired nutritional or biochemical properties. The present invention is further directed to a method of preparing an insoluble matrix-immobilized surfactant-coated lipase or phospholipase complex and of a process, of modifying oils and fats using an insoluble matrix-immobilized surfactant-coated lipase or phospholipase complex.
The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.
It is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
According to the present invention surfactant-coated lipases or phospholipases are immobilized onto insoluble matrices by three different methods: (i) immobilization through hydrophobic (physical) adsorption on inorganic or organic insoluble matrices; (ii) immobilization through ionic interactions on various ion exchange resins (polar or apolar matrices); and (iii) immobilization through covalent immobilization to insoluble matrix such as Eupergit (organic matrix).
The immobilized surfactant-coated lipases prepared according to the procedures described herein were used to catalyze inter-esterification reactions between triglycerides and fatty acids, one-step alcoholysis reactions between triglycerides and fatty alcohols for production of wax esters, and also trans-esterification reactions between two different triglyceride molecules or between two different oils.
The results indicate that coating lipases with a lipid surfactant, such as, but not limited to, fatty acid sugar ester types, lead to activation of the lipases for use in organic synthesis and in most cases the modification process converts relatively inactive crude lipases to highly active biocatalysts. To develop an efficient enzymatic inter/trans-esterification bioreactor from which the lipase enzyme can be easily recovered or used continuously, surfactant-lipase complexes immobilized on organic and inorganic matrices, were used.
It was found that surfactant-coated lipases immobilized on an organic or inorganic matrix showed high inter/trans-esterification activity and only slight activity losses in five consecutive inter-esterification runs using the same biocatalyst batch. It was further found that granulation of the matrix-bound, surfactant-treated enzyme considerably enhanced the stability of the enzyme, permitting its repeated use without substantial loss of activity.
The immobilized surfactant-lipase complexes prepared according to the present invention were used for the preparation of structured triglycerides which have potential applications in medicine and the food industry. The triglycerides of interest that were synthesized according to the method of the present invention were produced by inter-esterification of long-chain triglycerides, such as the hard fraction of palm oil, with short-chain fatty acids such as capric acid. Immobilized surfactant-coated lipase catalyzed reactions yielded predominantly products with 1,3 -positional specificity for the triglycerides of interest. Mono- and di-glycerides were also produced in a hydrolysis side reaction and their percentage was typically less than 7 weight percent of the initial triglyceride concentration. The operational stability of surfactant-lipase complexes immobilized on different solid matrices was 99 very high., particularly following the optional granulation step, and no significant enzyme activity losses were observed.
Inter-esterification reactions using the immobilized surfactant-lipase complexes were also carried out to obtain fats of special characteristics with regard to their physical properties. For example, liquid olive oil was trans-esterified with the hard fraction of palm olein in order to obtain blends of oil for preparation of healthier olive oil based margarines. This enzymatic process is a useful alternative for chemical oil hydro genation or interesterification processes.
Thus, in accordance with the teachings of the present invention there is provided a lipase preparation which includes an insoluble matrix and a surfactant-coated lipase complex immobilized onto the insoluble matrix.
As used herein in the specification and in the claims section below the term "lipase" is not limited to this specific enzyme, but is meant to embrace also similar enzymes such as phospholipase, proteases and glycosidases. Other suitable enzymes will be readily apparent to the skilled chemist, and are therefore not listed herein, for the sake of brevity.
According to a preferred embodiment the complex is immobilized to the insoluble matrix via hydrophobic (physical) interaction, ionic interaction or via covalent immobilization.
In a preferred embodiment of the invention the insoluble matrix is an inorganic insoluble matrix, the term "insoluble" referring to its lack of solubility in both polar (e.g., water) and non-polar (hydrophobic) solvents. Preferably, the inorganic insoluble matrix according to the present invention is alumina, aluminium stearate, Celite, calcium carbonate, silica gel, charcoal, calcium sulfate, ion-exchange resin, such as, but not limited to, Amberlite and Dowex. For physical immobilization, most preferably the inorganic insoluble matrix employed is diatomaceous earth (DE). For ionic immobilization most preferably the inorganic insoluble matrix employed is Amberlite and Dowex, which are strong ion exchangers.
Suitable organic solid matrices according to the present invention include Eupergit for covalent immobilization and ethylsolfoxycellulose for ion interaction. Any other suitable organic solid matrix may also be used without exceeding the scope of the invention.
In another preferred embodiment of the present invention the lipase represents 2-20. preferably 5- 11, weight percent of the surfactant-coated lipase complex. In yet another preferred embodiment of the present invention the lipase represents 0.01-1 weight percent of the preparation. Preferably the lipase represents about 0.7 weight percent of the preparation.
According to a preferred embodiment of the invention the surfactant employed is a lipid, which includes a fatty acid conjugated to a hydrophihc moiety. The fatty acid is preferably monolaurate, monomyristate, monopalmitate, monostearate, dilaurate, dimyristate, dipalmitate, distearate, trilaurate, trim3rristate, tripalmitate or tristearate. The hydrophilic moiety is preferably a sugar, such as, but not limited to, sorbitol, sucrose, glucose and lactose, a phosphate group, a carboxylic group or a polyhydroxylated organic residue. Typically, the fatty acid and the hydrophilic moiety are conjugated via an ester bond.
According to another preferred embodiment of the invention the lipase is derived from a microorganism or a multicellular organism. Species known to be used for lipase extraction include Burkholderia sp., Candida antarctica B, Candida rugosa, Pseudomonas sp., Candida antractica A, Porcine pancreas, Humicola sp., Mucor miehei, Rhizopus javan., Pseudomonas fluor, Candida cylindrcae, Aspergillus niger, Rhizopus oryzae, Mucor javanicus, Rhizopus sp., Rhizopus japonicus and Candida antractica.
According to a preferred embodiment of the invention the lipase preparation maintains hpase catalytic activity in an organic solvent. Lipase catalytic activity include hydrolysis, esterification, inter-esterification, trans-esterification, acidolysis and alcoholysis, preferably with 1,3 -positional specificity with respect to triacylglycerols. The organic solvent is typically a hydrophobic solvent, such as, but not limited to, n-hexane, toluene, iso-octane, -octane, benzene, cyclohexane and di-iso-propylether.
Further according to the present invention there is provided a method of preparing an insoluble matrix-immobilized surfactant-coated lipase complex. The method includes the following method steps, wherein in a first step a lipase, an insoluble matrix and a surfactant are contacted in an aqueous solution, preferably a buffered solution. Second, conditions (e.g., sonication) are provided for the formation of the matrix-immobilized surfactant-coated lipase complex. Two alternative schemes are available in this respect. In the first the lipase is first interacted with the surfactant and only thereafter the surfactant-coated lipase is interacted with the matrix. Whereas in the second, the lipase is first interacted with the matrix and only thereafter the matrix immobilized lipase is interacted with the surfactant.
According to a preferred embodiment, the method further includes the step of separating the matrix-immobilized surfactant-coated lipase complex from the aqueous solution.
According to still another preferred embodiment of the invention the method further includes the step of drying the matrix-immobilized surfactant-coated lipase complex. Drying is preferably effected via freeze drying, fluidization or in an oven. Following drying, the matrix-immobilized surfactant-coated lipase complex preferably includes less than 100, more preferably less than 50, most preferably less than 20 parts per million water content by weight.
In a preferred embodiment of the method according to the present invention, contacting the lipase, insoluble matrix and the surfactant within the aqueous solution is effected by dissolving the surfactant in an organic solvent (e.g., ethanol) for obtaining a dissolved surfactant solution, mixing the lipase and the dissolved "surfactant solution (e.g., dropwise) in the aqueous solution; sonicating the resulting suspension; and adding the insoluble matrix into the aqueous solution. Alternatively, the lipase is first interacted with the insoluble matrix and only thereafter with the surfactant.
According to a preferred embodiment, the insoluble matrix of the above-described lipase preparation is modified with a fatty acid derivative. This is to permit the immobilization of a hydrophobized lipase on a hydrophobized carrier, such as aluminium stearate, fatty-acid derivative-treated Celite and apolar or weak-polar ion-exchange resins, in order to prepare highly active enzymes.
Further according to the present invention there is provided a process of preparing structured triacylglycerois by esterification, trans-esterification, inter-esterification, acidolvsis or alcoholysis between two substrates effected by contacting an insoluble matrix-immobilized surfactant-coated lipase complex with the substrates. Contacting the matri -immobilized surfactant -coated lipase complex with the substrates is preferably effected in the presence of an organic solvent.
In a preferred embodiment, at least one of the substrates is an oil, a fatty acid or a triacylglycerol. The oil may be any of the above listed oils. The fatty acid is a medium or a short-chain fatty acid or an ester derivative thereof. A suitable fatty acid is, for example, oleic acid, palmitic acid, linolic acid, linolenic acid, stearic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and their ester derivatives.
In a preferred embodiment of the invention contacting the matrix-immobilized surfactant-coated lipase complex with the substrates is effected within a reaction reactor, e.g., a tank reactor or a fixed-bed reactor.
Further according to the present invention there is provided a process of changing the physical properties of oils/fats (e.g., triacylglycerols) by trans-esterification or inter-esterification between at least two oil/fat substrates by contacting an insoluble matrix-immobilized surfactant-coated lipase complex with the substrates, preferably in the presence of an organic solvent.
Further according to the present invention there is a process of changing the physical properties of long-chain triglycerides (LCT) and long-chain fatty alcohols (LCFAL) to produce wax esters by alcoholysis between at. least two such substrates by contacting an insoluble matrix-immobilized surfactant-coated lipase complex with the substrates, preferably in the presence of an organic solvent.
According to a preferred embodiment, the matrix-immobilized surfactant-coated lipase complex represents 2-30 weight percent of the substrates. In another preferred embodiment the oil/fat substrates are hquid oils and solid fats. The oil may be any of the above listed oils in a native or hydrogenated form.
Further according to the present invention there is provided a triacylglycerol prepared according to the above process. The triacylglycerol serves an application such as a cocoa butter substitute, human milk fat-like, triglycerides for special diets or structured triglycerides for medical applications.
Yet further according to the present invention there is provided a preparation which includes a lipase and an organic solvent. The lipase possessing both esterification (inter- and trans-esterification), acidolysis, alcoholysis and hydrolysis catalytic activities with respect to substrates, yielding esterificadon and hydrolysis products, respectively. The hydrolysis products represent less than about 7, preferably less than about 5, more preferably less than about 3 weight percent of the products.
Examples Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non-limiting fashion.
Experimental Procedures Materials Different crude lipase preparations were tested in this study. Table 1 below lists commercially available lipase preparations that were employed in this study, as well as their species source and supplier. All fatty acids and triglycerides employed in this study were obtained from Fluka (Switzerland) and, as reported by the supplier, were at least 99 % pure. Olive oil, sunflower oil, palm oil, canola oil, corn oil and Nigella sativa oil were obtained from local suppliers in the Galilee area, Israel. Fish oil, tris(hydroxymeth3rl)ammomethane and the inorganic matrices used as supports for the surfactant-coated lipase complexes, including DE. alumina and silica gel were obtained from Sigma (USA). 6 30 Analytical grade n-hexane and other solvents employed, all of analytical grade, were from Bio Lab (Israel). Sorbitan fatty acid esters including sorbitan monolaurate, sorbitan monomyristate, sorbitan monopalmitate and sorbitan monostearate and sucrose fatty acid esters including mixtures of mono-, di- and tristearate sucrose esters of variable HLB values were obtained from Kao Pure Chemicals Ind. (Tokyo, Japan). Tris(Hydroxymethyl)aminomethane (tris) was from Sigma (USA). Inorganic and organic matrices used as supports for the modified lipases include diatomaceous earth (DE), alumina and silica gel; ionic exchange resins were purchased from Sigma, USA. Eupergit C and Eupergit C 250L (macroporous, spherical, approximate diameter 150 and 200 urn, respectively) were from Ehom (Germany).
Table I Lipase modification and immobilization through physical adsorption Crude enzyme was first coated with lipid surfactant or other enzyme activators e.g. gum Arabic or polyethylene glycol. A typical enzyme modification and immobilization procedure was as follows: crude enz3rme (lipase, phospholipase, protease and glycosidases; protein content approximately 150mg/L), was dissolved in 1L phosphate or tris buffer solution with an appropriate pH, and magnetically stirred at 10 °C for 30min. A lipid surfactant or other enzyme activator (0.5g) dissolved in ethanol (20ml) or other solvents was added dropwise into the stirred solution. The resulting enzyme solution was sonicated for 15min and then vigorously stirred at 10 °C for 3 hours. An insoluble organic (20 g such as polypropylene, aluminium stearate or chitin) or inorganic matrix (20 g such as Celite, alumina, silica gel or ceramic support) was added into the stirred enzyme solution. The solution was magnetically stirred for a further 5 hours at 10 °C. The precipitate was collected by centrifugation at 12000rpm (Sorval Centrifuge, model- RC-5B) or by filtration, and then was treated by one of two different methods as follows: 1. The wet precipitate was lyophilized after freezing overnight at -20 °C. The formed powder can be directly used for batch enzymatic reactions or granulated for obtaining particulated modified and immobilized enzyme with a particle size of 50-1000μη . The granulation process was performed using various binding reagents such as starch, methyl or ethyl cellulose, gums, agarose or other binders. For example, the granulation with starch was conducted as follows: Starch solution (4 g starch/20ml water) was converted to gel at 70 °C. The gel was cooled down to 60 °C and then introduced to the modified and immobilized enzyme wet powder. The mixture was homogenized in a high-speed mixer followed by extruding and drying at 40-60 °C for 48 hours. The immobilized enzyme was sieved to obtain particles in the range of 50-1000 μπι. This particulated enzyme was used mainly in packed columns. 2. The wet precipitate formed after modification and immobilization was directly granulated with starch or other binding reagents as described above.
Enzyme modification and immobilization through ionic adsorption The above-described modification, immobilization and granulation procedures were also used in conjunction with ion-exchange resins. The types of resin used include: strong and week basic anion exchange resins, strong and weak acidic cationic exchange resins and weak-polar and apolar ion-exchange resins. Examples of commercially available resins used in the experiments (obtained from Sigma, USA) include: Dowex 22, Dowex 1x2-400, Dowex, 2x8-100, cellulose phosphate, Amberlite ERA-95. Amberlite IRA-200, Amberlite IEA-900, Amberhte XAD-7, Amberlite XAD-16, DiannonSA-lOA, Ectoela cellulose, Sephadex and sulfoxyethylcellulose. A typical modified immobilized enzyme was prepared according to the aforementioned procedure.
Enzyme modification and immobilization through covalent binding Two different immobilization procedures were adopted. According to the first, the enzyme was primarily coated with a surfactant and then the lipase-surfactant complex was covalently linked to an Eupergit matrix, which contains active oxirane groups. To this end, crude lipase (1 gram protein) was dissolved in 1 liter tris or phosphate buffer pH 5.8. The enzyme solution was vigorously stirred with a magnetic stirrer at 10 °C for 30 minutes. Sorbitan mono-stearate (0.5 grams) dissolved in 30 ml ethanol were added dropwise to the stirred enzyme solution. The resulting colloidal enzyme solution was sonicated for 10 minutes and then stirred for 3 hours at 10 °C. Eupergit C or Eupergit C 250L (125 grams) and 12 ml solution of 5 % hydrogen peroxide were added into the enzyme solution and the resulting suspension was gently handshaken for 1 minute, and then incubated for 48 hours at 23 °C. The precipitate was filtered, washed with tris or phosphate buffer pH 5.8, and was freeze-dried overnight.
According to the second procedure, the lipase was first bound covalently to an Eupergit matrix and then the bound lipase was coated with a surfactant. The chemistry involved in this procedure is depicted in Figure 2.
To this end, crude lipase (1 gram protein) was dissolved in 1 liter tris or phosphate buffer pH 5.8. The enzyme solution was vigorously stirred with a magnetic stirrer at 10 °C for 30 minutes. Eupergit C or Eupergit C 250L (125 grams) and 12 ml solution of 5 % hydrogen peroxide were added into the enzyme solution and the resulting suspension was gently handshaken for 1 minute and then incubated for 48 hours at 23 °C. Sorbitan mono-stearate (0.5 grams) dissolved in 30 ml ethanol was added dropwise to the suspension under a gentle shake. The resulting suspension was sonicated for 10 minutes and incubated at 10 °C for 6 hours. The precipitate was filtered, washed with tris or phosphate buffer pH 5.8, and then freeze-dried overnight.
As a control for the activity of the covalently immobilized lipases, the same immobilization procedures were followed however without adding surfactant to the enzyme solution.
To this end, crude lipase (1 gram protein), was dissolved in 1 liter tris or phosphate buffer pH 5.8. The enzyme solution was vigorously stirred with a magnetic stirrer at 10 °C for 30 minutes. Eupergit C or Eupergit C 250L (125 grams) and 12 ml solution of 5 % hydrogen peroxide were added into the enzyme solution and the resulting suspension was gently handshaken for 1 minute, and then incubated for 48 hours at 23 °C. The precipitate was filtered, washed with tris or phosphate buffer pH 5.S, and then was freeze-dried overnight.
Protein determinations according to the Bradford method indicated that all enzyme preparations prepared according to this method contained 0.9 - 1.5 wt % protein.
Reaction models Three different reaction models were used to test the activity of the modified and immobilized enzymes, compared to that of the crude enzymes and of the immobilized enzymes without modification. 1. Esterification reaction between lauric acid and dodecyl alcohol in an organic solvent system or in a solvent-free system.
The esterification reaction was initiated by adding 10 mg lipase preparation to 10 ml n-hexane that contained, typically, 200 mg lauric acid and 186 mg dodecyl alcohol. The reaction was magnetically stirred at 40° C. Samples were periodically withdrawn (50 μΐ), filtered with a Millipore filter (0.45 μπι) and then mixed with a similar volume of n-hexane solution containing n-hexadecane as an internal standard. 2. Transesterification reaction between the two triglycerides; tripalmitin and tristearin in an organic solvent system or in solvent-free system.
The transesterification reaction was initiated by adding 10 mg lipase preparation to 10 ml n-hexane that contained, typically, 40 mg tripalmitin and 40 mg tristearin. The reaction was magnetically stirred at 40° C. Samples were periodically withdrawn (50 μΐ), filtered with a Millipore filter (0.45 μπι) and then mixed, with a similar volume of n-hexane solution containing n-hexadecane as an internal standard. 3. Alcoholysis reaction between Olive oil and cetyl alcohol in organic solvent or solvent-free systems.
The alcoholysis reaction was initiated by adding 10 mg lipase preparation to 10 ml n-hexane that contained, typically, 500 mg olive oil, and 500 mg cetyl alcohol. The reaction solution was magnetically stirred at 40 °C. Samples (50 μΐ) were periodically removed, filtered with Millipore filters (0.45 μπι) and then mixed with a similar volume of n-hexane solution containing tridecanoin as an internal standard.
Unless otherwise, indicated, all experiments were conducted under the above-described conditions. Each esterification reaction was carried out in duplicate. In all experiments, n-hexane was dried over molecular sieves to minimize its water content down to 6 mg/liter. Thus, water concentration all reaction systems was less than 30 mg/liter.
Protein content The protein content of the modified lipases, and the modified and immobilized lipases was determined by the microkejldahl method.
Enzyme activity in a batch system The activity of the activated modified enzyme, modified and- immobilized enzyme on insoluble matrix, crude enzymes and immobilized enzymes in insoluble matrix, was tested using a 1ml vials containing the substrates. The vials were shaken at 40 °C and samples were analyzed after certain time intervals. Reaction rates were determined at substrate conversions less than 7% per mg of protein.
Operational stability of modified and immobilized enzyme The operational stability of the particulated modified and immobilized enzymes was tested in a jacketed column reactor (0.5cm i.d. and 15cm long) using the alcoholysis of olive oil and cetyl alcohol in n-hexane as a reaction model. The enzyme particles were packed in the column and the substrate solution was recirculated through the packed enzyme. The circulation was stopped after one hour and the reaction solution was analyzed. After each run the solution was discarded and the packed immobilized enzyme was washed with organic solvent (n-hexane) before charging a fresh substraie solution. This procedure was repeated 10-20 times.
EXPERIMENTAL RESULTS Example 1 Protein content of the lipase preparations The protein content of the different crude lipases, lipases modified with sorbitan monostearate (SMS), lipases immobilized on Celite and SMS-modified lipases immobilized on Celite, was measured as described above. The results are shown in Table II below.
The results show that there is fairly wide variation in protein concentration between the various preparations. For the surfactant-coated, matrix-immobilized enzymes, the protein content varied from 0.05 % to 1.12 %, by weight, according to the enzyme used in the preparation. Similar variation was seen when one enzyme, Lilipase, was treated with different lipid surfactants or other ■ activating agents, and, optionally, immobilized on Celite. The results of this investigation are shown in Table III.
Table II LiliDase A-10FG Enzyme Protein content %) Lipase crude 4.6 Lipase +SMS 1.62 Lipase +SMS/Celite 0.11 Lipase /Celite 0.1 Lipase M Enzyme Protein content (%) Lipase crude 0.96 Lipase +SMS 1.8 Lipase +SMS/Celite 0.12 Lipase /Celite 0.1 Lipase G - Amano 50 Enzyme Protein content (%) Lipase crude 9.65 Lipase +SMS 1.11 Lipase +SMS/Celite 0.06 Lipase /Celite 0.29 Lipase A- Amano 6 Enzvme Protein content (%) Lipase crude 21.63 Lipase +SMS 4.85 Lipase +SMS/Celite 0.225 Lipase /Celite 0.2 Table II continued Lipase Saiken 100 Enzyme Protein content (%) Lipase crude 4.84 Lipase +SMS 2.87 Lipase +SMS/Celite 0.06 Lipase /Celite 0.04 Lipase F P-15 Enzvme Protein content (%) Lipase crude 49.2 Lipase +SMS 9.31 Lipase +SMS/Celite 0.70 Lipase /Celite 0.47 Lipase F -EC Enzyme Protein content (%) Lipase crude 49.7 Lipase +SMS 7.2 Lipase +SMS/Celite 1.12 Lipase /Celite 0.2 Lipase EC Enzvme Protein content (%) Lipase crude 36.8 Lipase +SMS 6.5 Lipase +SMS/Celite 0.48 Lipase /Celite 0.39 Table II continued Lipase PS Enzyme Protein content (%) Lipase crude 7.5 Lipase +SMS 0.72 Lipase +SMS/Celite 0.16 Lipase /Celite 0.08 Lipase Newiase F Enzyme Protein content (%) Lipase crude 25.1 Lipase +SMS 2.17 Lipase +SMS/Celite 0.24 Lipase /Celite 0.013 Lipase LP Enzvme Protein content (%) Lipase crude 6.16 Lipase +SMS 4.6 Lipase +SMS/Celite 0.65 Lipase /Celite 0.21 Lipase AY - Amano 30 Enzyme Protein content (%) Lipase crude 5.14 Lipase +SMS 2.6 Lipase +SMS/Celite 0.05 Linase /Celite 0.05 Table III Enzvme Protein content (%) Lilipase+sorbitan monostearate 1.614 Lilipase+sorbitan monostearate/Celite 0.112 Lilipase+sucrose ester HLB=5 1.0 Lilipase+sucrose ester HLB=5/Celite 0.128 Lilipase+sucrose ester HLB=11 0.15 Lilipase+sucrose ester HLB=11/Celite 0.051 Lilipase+sucrose ester HLB=16 0.1 Lilipase+sucrose ester HLB=16/Celite 0.04 Lilipase+sorbitan monolaurate no precipitate Lilipase+sorbitan monolaurate/Celite 0.128 Lilipase+sorbitan tristearate 1.436 Lilipase+sorbitan tristearate/Celite 0.134 Lilipase+sorbitan trioleate no precipitate j Lilipase+sorbitan trioleate/Celite 0.115 Lilipase+monooleate no precipitate Lilipase+monooleate/Celite 0.140 Lilipase+lecithin no precipitate Lilipase+lecithin/Celite 0.16 Lilipase+stearic acid 1.65 Lilipase+stearic acid/Celite 0.108 Lilipase+Octadecanoic acid 1.17 I Lilipase+Octadecanoic acid/Celite 0.102 Lilipase polyoxyethylene-8-stearate 2.35 Lilipase polvoxyethvlene-8-stearate/Celite 0.115 Lilipase +polyethylene glycol no precipitate j Lilipase +polyethyleneglycol/Celite 0.10 Lilipase gum Arabic no precipitate Lilipase gum Arabic/Celite 0.172 Example 2 Esterification. transesterification and alcohoivsis activities of the lipase preparations A comparison was made of the enzymatic activities of the various lipase preparations ( prepared as described above). For the purposes of this comparison, the results (shown in Table TV) are presented as reaction rates (ri).
Table IV Lilipase A-10FG Enzyme ri ri ri (alcoholysis) (esterification) (transesterificatio (,umol/min.mg ^mol/min.mg n) protein) protein) ^moymin.mg protein) Crude 0.16 0.01 0 Lipase+SMS 7.43 5.2 2.1 Lipase+SMS/Celite 27.4 18.1 7.1 Lipase/Celite 4.5 0.8 0.4 Lipase M Enzyme ri ri ri (alcoholysis) (esterification) (transesterificatio ^mol/min.mg ^mo mi .mg n) protein) protein) ^mo min.mg protein) Crude 0.2 0 0 Lipase+SMS 6.7 4.8 2.0 Lipase+SMS/Celite 22.3 16.4 6.7 Lipase/Celite 3.2 0.1 0.3 Table IV continued Lipase PS Enzyme ri ri ri (alcoholysis) (esterification) (tr ans e sterificatio ^mol/min.mg ^mol/min.mg n) protein) protein) ^mol/min.mg protein) Crude 0.3 ■ 0 0 Lipase+SMS 5.2 4.3 1.6 Lipase+SMS/Celite 18.3 12.5 6.5 Lipase/Celite 4.5 0.4 0.2 Lipase LP Enzyme ri ri ri (alcoholysis) (esterification) (transesterificatio (μιηοΐ/min.mg ^mo mi .mg n) protein) protein) ^moVmin.mg protein) Crude 0.3 0 0 Lipase+SMS 4.9 3.3 1.4 Lipase+SMS/Celite 15.5 9.5 2.8 Lipase/Celite 2.3 0.2 0.35 Lipase EC Enzyme ri ri ri (alcoholysis) (esterification) (transesterificatio ^mol/min.rng ^mo mi .mg n) protein) protein) ^mol/min.mg protein) Crude 0 0 0 Lipase+SMS 0.7 1.9 1.9 Lipase+SMS/Celite 1.9 10.3 5.4 Lipase/Celite 0.1 1.1 0.3 0 6 45 Table TV continued Lipase AY Amano 30 Enzyme n Π ri (alcoholysis) (esterification) (transesterificatio ^mol/min.mg ^mol/min.mg n) protein) protein) ^mol/min.mg protein) Crude 0 0 Lipase+SMS 0.3 0.7 Lipase+SMS/Celite 0.8 1.3 Lipase/Celite 0.05 0.4 Lipase G Enzyme n n ri (alcoholysis) (esterification) (transesterificatio (μιηοΐ/min.mg ^mo min.m n) protein) protein) ^mol/min.mg protein) Crude 0 0 Lipase+SMS 0.15 0 Lipase+SMS/Celite 0.4 0 Lipase/Celite 0 0 Lipase A Enzyme n n ri (alcoholysis) (esterification) (transesterificatio (μπιοΐ/mm.mg ^mo min.rn n) protein) protein) ^mol/min.mg protein) Crude 0 0 Lipase+SMS 0.5 0.1 Lipase+SMS/Celite 1.2 0.6 Lipase/Celite 0.1 0 Table TV continued Lipase F-AP15 Enzyme n n ri (alcoholysis) (esterification) (transesterificatio (μπΊθΙ/min.mg ^mol/min.mg n) protein) protein) (μπιοΐ/min.mg protein) Crude 0.3 0 0 Lipase+SMS 6.7 4.9 1.9 Lipase+SMS/Celite 26.4 12.7 5.4 Lipase/Celite 0.8 0.93 .3 Lipase F-EC Enzyme n n ri (alcoholysis) (esterification) (transesterificatio ^mol/min.mg (pmol min.mg n) protein) protein) (pmo min.mg protein) Crude 0 0 Lipase+SMS 3.4 1.5 Lipase+SMS/Celite 10.5 5.4 Lipase/Celite 0.6 0.6 Lipase Saiken 100 Enzyme ri n ri (alcoholysis) (esterification) (transesterificatio (pmol7min.mg ^mol/min.mg n) protein) protein) ^mol/min.mg protein) Crude 0.15 0 0 Lipase+SMS 6.9 4.2 2.4 Lipase+SMS/Celite 29.3 10.3 8.2 Lipase/Celite 1.2 3.2 0.4 Table IV continued Lipase Newlase F Enzyme n ri ri (alcoholysis) (esterification) (transesterificatio (μmol/mi .m (μΓηοΙ/min.mg n) protein) protein) ^moymi .m protein) Crude 0 0 0 Lipase+SMS 1.3 1.3 0.4 Lipase+SMS/Celite 6.4 6.8 0.5 Lipase/Celite 0.2 0.1 0 These results indicate that in their native form the crude lipases used in this study lack measurable esterification or transesterification activity with the low water concentrations used. In contrast, both modification with the surfactant sorbitan monostearate and, independently, immobilization onto Celite, resulted in detectable levels of esterification and transesterification.
When the enzyme was subjected to both of these treatments, however, the reaction rates of both the esterification and transesterification reactions studies increased to much greater levels. From the numerical results presented in Table IV, it is clear that there is an unexpected synergism between the two stages of modification, i.e., treatment with surfactant and immobilization onto the matrix.
Figure 3 presents the conversion of tripalmitin with time when DE-immobilized surfactant-coated Saiken-100 (triangles) and Lilipase A10-FG (squares) were used to catalyze the inter-esterification reaction of tripalmitin and capric acid. The inter-esterification reaction rates thus measured were 0.096 and 0.104 mmol/min.mg biocatalyst, respectively.
Example 3 Fatty acid specificity of immobilized surfactant-coated lipase complexes The specificity of the inorganic matrix-immobilized surfactant-coated lipase complexes of the present invention toward different fatty acid substrates was tested by monitoring the inter-esterification of fatty acids of various chain lengths with tripalmitin. The results are summarized in Table V below.
Reaction conditions were as follows: Inter-esterification activity of crude lipase preparations was tested in n-hexane using tripalmitin (50 mg) as a triacylglycerol substance and capric acid (35 mg) as a medium-chain fatty acid substance. Inter-esterification activities of 10 mg non-immobilized surfactant-coated hpase (5-10 % protein content), or of 20 mg of inorganic matrix surfactant-coated hpase (0.2-2 % protein content), in n-hexane (10 ml), were examined using the same substrates.
Table V Fatty acid Fatty acid chain Inter-esterification length rate (mmol/min.mg biocat.) Butyric acid (C ) 0.055 Hexanoic acid (C6) 0.06 Octanoic acid (C8) 0.09 Decanoic acid (CIO) 0.104 Laurie acid (C12) 0.15 Myristic acid (C14) 0.2 Palmitic acid (C16) 0.25 Stearic acid (CIS) 0.26 Oleic acid (C 1,8:1) 0.3 Arachidonic acid (C20) 0.28 Behenic acid (C22) 0.28 From Table V it can be seen that the immobilized surfactant-coated Lilipase complexes according to the present invention predominantly catalyzed the inter-esterification of fatty acids and tripalmitin with 1,3-positional specificity. The concentration of hydrolysis products did not exceed 5 wt % of the initial tripalmitin concentration.
It is further noted that the inter-esterification activity of the inorganic matrix-immobilized surfactant-coated lipase complexes according to the present invention was affected by the fatty acid chosen to be used as a substrate. Thus, fatty acids having longer alkyl chains, such as palmitic and stearic acids, are better substrates for the DE-immobilized surfactant-coated lipase complexes than fatty acids having shorter alkyl chains.
Example 4 Influence of surfactant choice on inorganic matrix-immobilized surfactant-coated lipase complexes Table VI below demonstrates that the type of sorbitan fatty acid ester selected for coating the lipase influences the inter-esterification activity of Celite-immobilized surfactant-coated lipase complexes.
When sorbitan monostearate was used for coating, the inter-esterification activity of the complex was the highest. However, using a shorter fatty acid chain length in the sorbitan ester led to decrease in the activity of the complex.
Table VI Lilroase A-10FG Enzyme ri ri ri (esterification) (transester (alcoholysi (mol/min.mg iiication) s) ((mol min. protein) (mol/min. mg mg protein) protein) Lilipase crude 0.16 0.01 0 Lilipase/Celite 4.5 0.1 0.4 Lilipase+sorbitan monostearate 7.43 5.75 1.2 Lilipase+sorbitan monostearate/Celite ! 27.4 15.5 2.3 Lilipase+sucrose ester HLB=5 23.6 4.5 3.5 Lilipase+sucrose ester HLB=5/Celite 22.4 7.5 5.5 Lilipase+sucrose ester HLB=11 31.1 12.5 6.2 Lilipase+sucrose ester HLB=11/Celite 25.3 30 8.2 Lilipase+sucrose ester HLB=16 8.5 2 1.1 Lilipase+sucrose ester HLB=16/Celite 16.2 12.5 4.2 Lilipase+sorbitan monolaurate 6.2 4 0.6 Lilipase+sorbitan monolaurate/Celite 7.1 11.5 2.1 Lilipase+sorbitan tristearate 10.1 4 1.9 Lilipase+sorbitan tristearate/Celite 22.5 31 7.2 Lilipase+sorbitan trioleate 18.3 7.5 2.6 Lilipase+sorbitan trioleate/Celite 27.3 20 9.3 Lilipase+ sorbitan monooleate 6.2 2.5 1.4 Lilipase+monooleate/Celite 8.5 10 4.2 Lilipase+lecithin 10.2 3.5 1.15 Lilioase+lecithin/Celite 16.2 10 3.2 Lilipase+stearic acid 6.3 3.75 1.6 Lilipase+stearic acid/Celite 13.4 14 5.3 Lilipase+Octadecanoic acid 6.2 3 0.81 Lilipase+Octadecanoic acioVCelite 14.6 11.5 3.4 Lilipase poly oxy e thylene - 8 - s tearate 6.5 4.4 2.1 Lilipase 13.5 16 6.2 polyoxvethylene-8-stearate/Celite Lilipase +polyethylenglycol 5.4 0 0 Lilipase +polvethvlenelvcol/Celite 9.2 0.4 0.4 Lihpase gum Arabic 9.3 2 0.5 Lilioase sum Arabic/Celite 11.1 5 1.1 Example 5 Physical binding of modified lipase to insoluble matrices The esterincation, transesterification and alcoholysis activity for Lilipase A-10FG immobilized on various insoluble matrices was measured, and compared with the activities of Lilipase A-10FG modified with sorbitan monostearate and immobilized on different inorganic matrices. The results are shown in Table VII.
Table VII Enzyme/Insoluble ri ri (transri matrix* (esterification) esterification) (alcoholysis) ^mol/min.mg ^mol/min.mg ^mol/min.m protein) protein) g protein) Lihpase A10-FG crude 0.16 0.01 0 Lihpase + SMS 7.43 5.2 2.1 Lihpase + SMS/Celite 27.4 18.1 7.1 (acid-washed) Lilipase/Celite 4.5 0.8 0.4 (acid-washed) Lihpase + SMS/Celite 25.4 13.5 6.0 (acid-nonwashed) Lilipase/Celite 3.5 0.5 0.1 (acid-nonwashed) Lilipase + SMS/fatty* 41.3 27.4 17.3 acid-treated Cehte Lilipase/fatty acid-treated 19.7 9.5 4.6 Celite Lilipase+ SMS /Alumina 23.2 11.1 5.4 LiliDase/Alumina 1.6 0.3 0.4 Lilipase + SMS 45.3 29.1 19.2 /Aluminium monostearate Table VII continued Lilipase/ Aluminium 19.2 9.8 6.1 monostearate Lilipase + SMS/Silica 21.3 10.8 5.7 Lilipase/Silica 3.2 0.4 0.2 Lilipase + SMS/Calcium 18.6 12.3 6.1 carbonate Lilipase/Calcium 2.4 0.4 0.2 carbonate Lilipase + SMS/ Calcium 16.6 11.3 5.6 sulfate Lilipase/Calcium sulfate 0.3 0.2 0.3 * Fatty acid-(or its derivative) treated Celite (hydrophobized Celite) was prepared as follows: Celite (100 g) was suspended in phosphate buffer solution (100 ml) of pH=5.7. A solution of free fatty acid or its derivative (stearic acid or fatty acid sugar ester) dissolved in ethanol (5g/30ml) was added dropwise to the vigorously stirred suspension at 70°C. The suspension was stirred for 2 h, filtered, washed with water and then lyophilized.
The most suitable carriers for the immobilized enzymes used in this study are aluminum monostearate and fatty acid-treated Celite. As can be seen in Table VII, nonmodified Lilipase immobilized on Aluminum monostearate or fatty acid treated- Celite gave relatively good activity in all of the three reaction models. The results presented in this Table prove that the enzyme modification with a surfactant in a first step and then immobilizing the modified enzyme on a fatty acid-treated insoluble matrix leads to a further increment in the activity of the enzyme. As can be seen in the above Table, the activity of the fatty acid derivative-modified and immobilized lipase on a fatty acid derivative-treated insoluble matrix (Aluminum monostearate, fatty acid derivative-treated Celite) is much greater than the activity of lipase immobilized on a fatty acid derivative-treated insoluble matrix Example 6 The effect of the choice of ion-exchange resin on enzvme activity The esterification, transesterification and alcoholysis activities of Lilipase A-10FG immobilized on various ion-exchange resins, and of the same enzyme modified with sorbitan monostearate prior to immobilization were compared. The results of this comparison (expressed as reaction rate, ri) are shown in Table VIII.
Table VIII Lilipase/Ion-exchange ri ri (trans- ri resin* (esterification) esterification) (alcoholysis) ^mol/min.mg ^mol/min.mg (μιηοΐ/πιίη.πι protein) protein) protein) Dowex 22 4.9 4.7 1.9 Dowex 22 + SMS 32.2 23.1 6.3 Dowex 1x2-400 6.9 3.5 1.1 Dowex 1x2-400 + SMS 29.6 25.4 6.1 Dowex2x8-100 5.5 4.7 2.2 Dowex2x8-100 + SMS 21.3 16.2 7.3 Cellulose phosphate 3.5 0.2 0.1 Cellulose phosphate + 6.3 1.5 1.1 SMS Amberlite IRA-95 7.6 0.8 0.9 Amberlite IRA-95 + SMS 26.2 12.5 2.3 Amberlite IRA-200 , 9.2 3.1 1.4 Amberlite IRA-200 + 28.6 18.9 5.3 SMS Amberlite IRA- 900 . 6.1 4.2 2.3 Amberlite IRA-900 + 37 28.3 8.6 SMS DiannonSA-lOA 6.1 2.8 1.2 DiannonSA-lOA + SMS 31 19.5 11.3 Ectoela cellulose 5.4 2.3 1.7 Ectoela cellulose + SMS 29.5 12.2 5.7 Sephadex 1.5 0.2 0.1 Sephadex + SMS 2.9 0.9 0.8 Sulfoxyethylcellulose 5.6 3.2 2.5 Sulfoxyethylcellulose + 32.3 17.0 12.6 SMS Amberlite XAD-7 8.3 4.5 3.8 (Weak-polar) Amberlite XAD-7 + SMS 37.3 29.5 17.5 Amberlite XAD-16 6.7 6.5 4.3 (apolar) Amberlite XAD-16 + SMS 33.4 24.4 14.3 * All ion-exchange resins were purchased from Sigma, USA.
These results demonstrate the dramatic increase in esterification and trans-esterification activity of the modified enzymes upon immobihzation.
Furthermore, it can be seen from Table VIII that ion-exchange resins containing hydrophobic groups in their structure behave much better as carriers for the surfactant-modified enzymes.
Example 7 Biosynthesis of structured triglycerides from different oils using inorganic matrix-immobilized surfactant-coated lipase complexes Table IX below demonstrates the rates of inter-esterification reactions between different oils and capric acid in n-hexane system and in a solvent free system at 60 °C. The inter-esterification reactions were catalyzed by DE-immobilized surfactant-Lilipase A10-FG complexes.
DE-immobilized surfactant-Lilipase complexes predominantly catalyzed the inter-esterification of various oils with capric acid in n-hexane and solvent free systems. The highest inter-esterification reaction was obtained when olive oil was employed. Similar reaction rates where obtained when the inter-esterification reactions were carried-out in a solvent-free system.
Table ΓΧ Source of oil R.R. (mmoL/min-mg biocat.) R.R. (mmol/min-mg biocat.) in n-hexane in solvent free system Olive oil 0.73 Fish oil 0.53 Sun flower oil 0.42 Palm oil 0.31 Canola oil 0.45 Corn oil 0.41 Nigelia sativa oil 0.46 Example 8 Operational stability of modified and immobilized enzvmes The stability of the enzyme preparations over repeated cycles of use was determined as described in the methods section above. For the purposes of this investigation, Lilipase A-10FG was used to catalyze the conversion of olive oil to a wax ester. Activity was measured in a 10-run experiment, each run requiring one hour for completion. ' The level of activity was measured as percentage conversion of the olive oil. The reaction conditions used were as follows: 100 ml of n-Hexane containing 20g olive oil and 20g cetyl alcohol recirculated over an immobilized enzyme packed-bed at a circulation rate of 2.3 ml/min at 40° C. The column used to pack the granulated enzyme was 12 cm long with an internal diameter of 0.75 cm. The results of this investigation are shown in figures 5 — 12.
Fig. 5 shows that the activity of Lilipase A-10FG immobilized on Celite (without modification) and granulated with 2% starch was low, and that the activity decreased with each re-use. Fig. 6 shows that the activity of the same lipase powder after modification with sorbitan monostearate and then immobilization on Celite (without granulation) was 9-fold higher than the activity of the same non- modified lipase. It can be seen from Fig. 2 that there was sharp activity loss after the first, second and the third runs, which can be attributed .to washing out of the immobilized enzyme. Figs. 7- 16 show that the enzyme activity in organic solvent can be essentially retained by granulation with different binding reagents such as starch, ethyl cellulose, gums, starch, etc. The granulation process also facilitates the flow in the packed column with enzyme. The binders used in these figures are as follows: Fig. 7 Starch 2% Fig. 8 Ethyl cellulose 2 % Fig. 9 Gum Arabic 2 % Fig. 10 Ethyl cellulose 2 % Fig. 11 Agarose 2% Fig. 12 Starch 4% Figs. 13 - 16 Starch 2 % Immobilization was performed on Celite in the experiments shown in figures 5 - 9 and 12 - 13, on Amberlite IRA-900 in the experiments shown in figures 10 and 11, on aluminium monostearate in figure 14, on Amberlite XAD-16 in figure 15 and on Amberlite XAD-7 in figure 16. In all cases where lipase was modified by surfactant, the surfactant used for this treatment was sorbitan monostearate, except for the experiment shown in figure 13, where the surfactant was sorbitan tristearate.
Example 9 Covalent binding of modified and non-modified lipases to Eupergit Lipases were covalentlv bound to Eupergit according to the manufacturer's specification. The covalent binding was carried out the two procedures described above.
Table X Lilipase A10-FG Enzyme form Conversion (%) Crude Lilipase A10-FG 2 Lilipase on Eupergit 4 Lilipase on Eupergit + SMS 19 Lilipase on Eupergit + SMS after 48h 26 Lipase LP Enzyme form Conversion ( ) Crude lipase LP 1 Lipase LP on Eupergit 2 Lipase LP on Eupergit + SMS ■ 14 Lipase LP on Eupergit + SMS after 48h 18 Lipase PS Enzyme form Conversion (%) Crude lipase PS 1 Lipase PS on Eupergit 2 Lipase PS on Eupergit + SMS 8 Lipase PS on Eupergit + SMS after 48h 12 It can be seen from Table X that different lipases show different inter-esterification activity when are treated similarly. This result is ascribed to the different sources of the lipases used. All crude hpases showed very low inter-esterification activity under the described conditions while their activity has slightly increased when they were covalently immobilized on Eupergit. It is interesting to notice that when lipases were coated with a surfactant their inter-esterification activity has significantly increased. The highest conversion of tripalmitin to its inter-esterification products with 1,3-positional specificity that was achieved after 2 h reaction, was when the lipases were first covalently immobilized on Eupergit and then coated with surfactant. Lilipase A10-FG coated with the surfactant and immobilized on Eupergit 3delded the highest inter-esterification activity within the three lipases tested in this respect (Table X).
Example 10 Effect of binders on the enzyme activity.
As previously mentioned, different binders have been used for the granulation of the modified-immobilized lipases. Table XI shows the average conversion of olive oil to its wax esters in the first and second runs, using different binders for granulating Lilipase A10-FG modified with sorbitan monostearate and immobilized on Celite. The percentage of all binders was 2% dry weight of the granules. In these experiments, the granulated enzyme was packed in a column and used in 10 runs.
The average conversion of olive oil to its wax esters in the first and second runs using Lilipase A 10FG modified with sorbitan monostearate and immobilized on Celite and then granulated with different binders (2%). Reaction conditions: 100ml of n-Hexane containing 2g olive oil and 2g cetyl alcohol recirculated over an immobilized enzyme packed-bed at a circulation rate of 2.5 ml7min and at 40°C. Column dimensions: 12 cm long, 0.75 cm i.d.
Table XI Binder Conversion (%) Starch 92 Ethyl cellulose 44.6 Methyl cellulose 3S.1 Agarose 16.8 Gelatin Inactive Polyvinylpyrrollodone Inactive Gum Arabic 49.1 Gum Xan 33.2 Gum Karaya 49.5 Gum Tragacanth 20.1 Gum Locas 33.6 From the above table it may be concluded that starch, Gum Arabic and Gum Karaya are the most effective binders of those tested in this study, that yielded active biocatalysts.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
Claims (51)
1. A lipase preparation comprising an insoluble matrix and a surfactant-coated lipase complex immobilized onto said insoluble matrix.
2. The lipase preparation of claim 1, wherein the surfactant-coated lipase complex is covalently, ionicalJy or physically bound to the insoluble matrix.
3. The lipase preparation of claim 1, wherein the insoluble matrix is selected from the group consisting of an inorganic insoluble matrix and an organic insoluble matrix.
4. The lipase preparation of claim 3, wherein the inorganic insoluble matrix is selected from the group consisting of alumina, diatomaceous earth, Celite, calcium carbonate, calcium sulfate, ion-exchange resin, silica gel and charcoal.
5. The lipase preparation of claim 4, wherein the ion-exchange resin is. selected from the group consisting of Amberlite and Dowex.
6. The lipase preparation of claim 3, wherein the organic insoluble matrix is selected from the group consisting of Eupergit, ethylsulfoxycellulose and aluminium stearate.
7. The lipase preparation of claim 1, wherein the content of the lipase is 2-20 weight percent of the surfactant-coated lipase complex.
8. The lipase preparation of claim 1, wherein the content of the lipase is 0.01-1.0 weight percent of the preparation.
9. The lipase preparation of claim 1, wherein the surfactant in the surfactant-coated lipase complex includes a fatty acid conjugated to a hydrophilic moiety.
10. The lipase preparation of claim 9, wherein the fatty acid is selected from the group consisting of monolaurate, monomyristate, monopalmitate, monostearate, dilaurate, dimyristate, dipalmitate, distearate, trilaurate, trimyristate, tripalmitate and tristearate.
11. The lipase preparation of claim 9, wherein the hydrophilic moiety is selected from the group consisting of a sugar, a phosphate group, a carboxylic group and a hydroxylated organic residue. 145503/3 63
12. The lipase preparation of claim 11, wherein the sugar is selected from the group consisting of sorbitol, sucrose, glucose and lactose.
13. The lipase preparation of claim 9, wherein the fatty acid and the hydrophilic moiety are conjugated via an ester bond.
14. The lipase preparation of claim 1, wherein the lipase is derived from a microorganism.
15. The lipase preparation of claim 1, wherein the lipase is derived from a species selected from the group consisting of Burkholderia sp., Candida antarctica B, Candida rugosa, Pseudomonas sp., Candida antarctica A, Porcine pancreas lipase, Humicola sp., Mucor miehei, Rhizopus javan., Pseudomonas fluor., Candida cylindrcae, Aspergillus niger, Rhizopus oryzae, Mucor javanicus, Rhizopus sp., Rhizopus japonicus and Candida antarctica.
16. The lipase preparation of claim 14, wherein the lipase is derived from a multicellular organism.
17. A lipase preparation comprising an insoluble matrix and a surfactant-coated lipase complex immobilized onto an insoluble matrix, said lipase preparation being provided in an organic solvent. 145503/3 64
18. The lipase preparation of claim 17, wherein the organic solvent is selected from the group consisting of n-hexane, toluene, iso-octane, n-octane, benzene, cyclohexane and di-iso-propylether.
19. The lipase preparation of claim 17, for use as a catalyst for esterification, inter-esterification and trans-esterification of oils and fats and alcoholysis of triglycerols and fatty alcohols.
20. The lipase preparation of claim 19 for use as a catalyst with 1,3-positional specificity with respect to triacylglycerols.
21. The lipase preparation of claim 1, wherein said preparation is in granulated form.
22. The lipase preparation of claim 1, wherein the insoluble matrix has been modified with a fatty acid derivative.
23. An enzyme preparation according to claim 1, for use in a reaction environment without the need for water addition.
24. A method for improving the stability of a surfactant-coated immobilized lipase complex, comprising granulating same prior to contacting it with the substrate to be reacted. 145503/5 65
25. A method of preparing an insoluble matrix-immobilized surfactant-coated lipase complex comprising, in any desired order, the steps of (a) contacting a lipase in an aqueous medium with a surfactant, at a concentration and temperature, and for a period of time sufficient to obtain a coating of said lipase; and (b) contacting said lipase in an aqueous medium, with an insoluble matrix, at a concentration, under conditions and for a period of time sufficient to obtain immobilization of said lipase on said matrix.
26. The method of claim 25, wherein said lipase is first contacted with the insoluble matrix, and thereafter with the surfactant.
27. The method of claim 25, wherein the lipase is first contacted with the surfactant, and thereafter with the insoluble matrix.
28. The method of claim 25, further comprising the step of: (c) separating the matrix-immobilized surfactant-coated lipase complex from the aqueous solution in which it was formed.
29. The method of claim 28, further comprising the step of: 145503/5 66 (d) drying the matrix-immobilized surfactant-coated lipase complex.
30. The method of claim 29, wherein drying is effected by freeze drying.
31. The method of claim 29, wherein the matrix-immobilized surfactant-coated lipase complex is dried to a water content of less than 100 parts per million by weight.
32. The method of claim .25, wherein the aqueous solution buffered aqueous solution.
33. The method of claim 25, wherein the lipase and surfactant are contacted in the aqueous medium by: (i) dissolving said surfactant, in an organic solvent for obtaining a dissolved surfactant solution; and (ii) mixing said lipase and said dissolved surfactant solution in said aqueous medium.
34. The method of claim 25, further comprising sonicating the aqueous solution. 145503/4 67
35. The method of claim 25, wherein the insoluble matrix is selected from the group consisting of alumina, diatomaceous earth, Celite, calcium carbonate, calcium sulfate, ion-exchange resin, silica gel, charcoal, Eupergit, ethylsulfoxycellulose, aluminium stearate and fatty acid derivative - treated Celite or other inorganic matrices.
36. The method of claim 25, wherein the surfactant includes a fatty acid conjugated to a hydrophilic moiety.
37. The method of claim 36, wherein the fatty acid is selected from the group consisting of monolaurate, monomyristate, monopalmitate, monostearate, dilaurate, dimyristate, dipalmitate, distearate, trilaurate, trimyristate, tripalmitate and tristearate.
38. The method of claim 36, wherein the hydrophilic moiety is selected from the group consisting of a sugar and a phosphate group and a carboxylic group and a polyhydroxylated organic residue.
39. The -method of claim 38, wherein the sugar is selected fro group consisting of sorbitol, sucrose, glucose and lactose.
40. The method of claim 36, wherein the fatty acid and the hydrophilic moiety are conjugated via an ester bond. 145503/2 68
41. The method of claim 25, wherein the lipase is derived from an organism.
42. The method of claim 41, wherein the lipase is derived from multicellular microorganism.
43. The method of claim 41, wherein the lipase is derived from a species selected from the group consisting of Burkholderia sp., Candida antarctica B, Candida rugosa, Pseudomonas sp., Candida antarctica A, Porcine pancreatic lipase, Humicola sp., Mucor miehei, Rhizopus javan., Pseudomonas fluor., Candida cylindrcae, Aspergillus niger, Rhizopus oryzae, Mucor javanicus, Rhizopus sp., Rhizopus japonicus and Candida antarctica.
44. A process for preparing structured triacylglycerols by esterification, acidolysis, trans-esterification, inter-esterification or alcoholysis between two substrates comprising contacting an insoluble matrix-immobilized surfactant-coated lipase complex with said substrates.
45. The process of claim 44, wherein the matrix-immobilized surfactant- coated lipase complex is contacted with the substrates in the presence of an organic solvent.
46. The process of claim 44, wherein at least one of the substrates is selected from the group consisting of an oil, a fatty acid, a triacylglycerol and a fatty alcohol.
47. The process of claim 46, wherein the oil is selected from the group consisting of olive oil, soybean oil, peanut oil, fish oil, palm oil, cotton seeds oil, sunflower oil, Nigella sativa oil, canola oil and corn oil.
48. The process of claim 46, wherein the fatty acid is selected from the group consisting of medium and short-chain fatty acids and their ester derivatives.
49. The process of claim 46, wherein the fatty acid is selected from the group consisting of oleic acid, palmitic acid, linolic acid, linolenic acid, stearic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and their ester derivatives.
50. The process of claim 44 which is carried out in a tank reactor or in a fixed-bed reactor.
51. A triacylglycerol prepared according to the process of claim 44, for use as a cocoa butter substitute, human milk fat-like triglycerides for special diets, or structured triglycerides for medical applications.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL145503A IL145503A (en) | 1999-03-22 | 2001-09-17 | Surfactant-lipase complex immobilized on insoluble matrix |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12908699A IL129086A0 (en) | 1999-03-22 | 1999-03-22 | Surfactant-lipase complex immobilized on insoluble matrix |
PCT/IL2000/000166 WO2000056869A2 (en) | 1999-03-22 | 2000-03-16 | Surfactant-lipase complex immobilized on insoluble matrix |
IL145503A IL145503A (en) | 1999-03-22 | 2001-09-17 | Surfactant-lipase complex immobilized on insoluble matrix |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145503A true IL145503A (en) | 2009-06-15 |
Family
ID=11072627
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12908699A IL129086A0 (en) | 1997-09-24 | 1999-03-22 | Surfactant-lipase complex immobilized on insoluble matrix |
IL145503A IL145503A (en) | 1999-03-22 | 2001-09-17 | Surfactant-lipase complex immobilized on insoluble matrix |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12908699A IL129086A0 (en) | 1997-09-24 | 1999-03-22 | Surfactant-lipase complex immobilized on insoluble matrix |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1163329A2 (en) |
JP (1) | JP2002539782A (en) |
KR (1) | KR100774281B1 (en) |
CA (1) | CA2368179A1 (en) |
IL (2) | IL129086A0 (en) |
NZ (1) | NZ514271A (en) |
WO (1) | WO2000056869A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL142952A (en) | 2001-05-03 | 2005-12-18 | Enzmotec Ltd | Process for enzyme-catalyzed production of 1,2 diacylated phospholipids |
KR100485090B1 (en) * | 2002-01-14 | 2005-04-22 | 주식회사 포스코 | Enzymes coated with ionic liquid |
IL152290A0 (en) * | 2002-10-14 | 2003-05-29 | Enzymotec Ltd | Immobilization of compounds on polymeric matrix |
US20060233863A1 (en) | 2003-02-10 | 2006-10-19 | Enzymotec Ltd. | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy |
IL158139A0 (en) | 2003-09-25 | 2004-09-27 | Enzymotec Ltd | Stabilized formulations of phosphatidyl serine |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
IL158555A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
US20050130937A1 (en) | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
MY142014A (en) * | 2004-04-08 | 2010-08-16 | Nisshin Oillio Group Ltd | A lipase powder, methods for producing the same and use thereof |
BRPI0513461A2 (en) | 2004-08-10 | 2011-05-10 | Enzymotec Ltd | Treatment methods requiring phyto ingredients |
US7473539B2 (en) | 2004-09-20 | 2009-01-06 | Sunho Biodiesel Corporation | Methods for producing alkyl esters |
JP4785174B2 (en) * | 2004-12-10 | 2011-10-05 | 株式会社豊田中央研究所 | Membrane protein composite material and method for producing the same |
PL2439268T3 (en) * | 2005-06-16 | 2016-06-30 | Dsm Nutritional Products Ag | Immobilized enzymes and methods of using thereof |
JP4917349B2 (en) | 2006-05-11 | 2012-04-18 | 日清オイリオグループ株式会社 | Recovery method of lipase activity |
IL180598A0 (en) * | 2007-01-08 | 2007-07-04 | Basheer Sobhi | Immobilized interfacial enzymes of improved and stabilized activity |
IL183084A0 (en) | 2007-05-09 | 2007-09-20 | Trans Biodisel Ltd | Modified-immobilized enzymes of high tolerance to hydrophilic substrates in organic media |
DE102008006716A1 (en) * | 2008-01-30 | 2009-08-13 | BAM Bundesanstalt für Materialforschung und -prüfung | Lipasenformulierung |
US8846338B2 (en) | 2008-08-07 | 2014-09-30 | Lipogen Ltd. | Processes for the preparation of phosphatides |
SG184349A1 (en) | 2010-04-26 | 2012-11-29 | Enzymotec Ltd | Methods and lipid compositions for promoting development of gut flora |
CN106536696B (en) | 2014-07-22 | 2023-12-29 | 日清奥利友集团株式会社 | Powder oil and fat composition, food containing powder oil and fat composition, and method for producing same |
CN108024550B (en) | 2015-09-24 | 2021-11-26 | 日清奥利友集团株式会社 | Powder fat composition and method for producing same |
WO2017126667A1 (en) | 2016-01-21 | 2017-07-27 | 日清オイリオグループ株式会社 | Powdering agent for liquid component |
CN108495918B (en) | 2016-01-21 | 2022-03-15 | 日清奥利友集团株式会社 | Powdering agent for liquid component |
CN108495904B (en) | 2016-01-21 | 2020-12-15 | 日清奥利友集团株式会社 | Thickening agent for liquid components |
US11219224B2 (en) | 2016-01-21 | 2022-01-11 | The Nisshin Oillio Group, Ltd. | Thickener for liquid component |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK638688D0 (en) * | 1988-11-16 | 1988-11-16 | Novo Industri As | PARTICULAR IMMOBILIZED LIPASE PREPARATION, PROCEDURE FOR PREPARING IT AND USING THEREOF |
JP2778135B2 (en) * | 1989-07-18 | 1998-07-23 | 味の素株式会社 | Preparation method of lipase-immobilized enzyme preparation |
JP3344738B2 (en) * | 1992-08-20 | 2002-11-18 | 天野エンザイム株式会社 | Immobilized modifying enzyme, ester synthesis method using the immobilized modifying enzyme |
JPH08511159A (en) * | 1993-05-20 | 1996-11-26 | ロダース・クロックラーン・ビー・ブイ | Immobilized lipase |
JPH07135972A (en) * | 1993-09-22 | 1995-05-30 | Ajinomoto Co Inc | Lipase preparation and modification of oil and fat using the lipase preparation |
CN1266460A (en) * | 1997-06-05 | 2000-09-13 | 卡尔金有限责任公司 | Diacrylglycerol acyl transferase proteins |
EP0882798A1 (en) * | 1997-06-06 | 1998-12-09 | Akzo Nobel N.V. | Process for the preparation of a monoester-containing esterification product of a polyoxyalkylated sucrose |
WO1999015689A1 (en) * | 1997-09-24 | 1999-04-01 | Enzymothec Ltd. | Surfactant-lipase complex immobilized on insoluble matrix |
-
1999
- 1999-03-22 IL IL12908699A patent/IL129086A0/en unknown
-
2000
- 2000-03-16 CA CA002368179A patent/CA2368179A1/en not_active Abandoned
- 2000-03-16 EP EP00911221A patent/EP1163329A2/en not_active Withdrawn
- 2000-03-16 KR KR1020017012028A patent/KR100774281B1/en active IP Right Grant
- 2000-03-16 WO PCT/IL2000/000166 patent/WO2000056869A2/en active IP Right Grant
- 2000-03-16 JP JP2000606728A patent/JP2002539782A/en active Pending
- 2000-03-16 NZ NZ514271A patent/NZ514271A/en not_active IP Right Cessation
-
2001
- 2001-09-17 IL IL145503A patent/IL145503A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ514271A (en) | 2003-08-29 |
IL129086A0 (en) | 2000-02-17 |
KR100774281B1 (en) | 2007-11-08 |
KR20020010129A (en) | 2002-02-02 |
JP2002539782A (en) | 2002-11-26 |
CA2368179A1 (en) | 2000-09-28 |
WO2000056869A3 (en) | 2001-02-08 |
EP1163329A2 (en) | 2001-12-19 |
WO2000056869A2 (en) | 2000-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6605452B1 (en) | Fatty acid polyol ester-coated lipase complex immobilized on insoluble matrix | |
IL145503A (en) | Surfactant-lipase complex immobilized on insoluble matrix | |
Mendes et al. | Properties and biotechnological applications of porcine pancreatic lipase | |
JP7213184B2 (en) | Enzymatic enrichment of n-3 fatty acids in the form of glycerides | |
Fernandez-Lafuente | Lipase from Thermomyces lanuginosus: uses and prospects as an industrial biocatalyst | |
Cho et al. | Immobilization of lipase for effective interesterification of fats and oils in organic solvent | |
Hernandez et al. | Hydrolysis of triacetin catalyzed by immobilized lipases: Effect of the immobilization protocol and experimental conditions on diacetin yield | |
JP4216082B2 (en) | Method for producing phospholipid | |
US5569594A (en) | Transesterification with lipase immobilized on a polymer containing epoxy and tertiary amino groups | |
Cieh et al. | Progress on lipase immobilization technology in edible oil and fat modifications | |
WO1990004033A1 (en) | Production of monoglycerides by enzymatic transesterification | |
JPH01262795A (en) | Immobilized enzyme and production thereof | |
JP5586855B2 (en) | Method for producing monoacylglycerol-rich oil and fat | |
AU773466B2 (en) | Surfactant-lipase complex immobilized on insoluble matrix | |
US20030175918A1 (en) | Method for increasing the performance of immobilzed biocatalysts, and catalysts obtained thereby | |
JP3929890B2 (en) | Method for producing diglyceride | |
JP3509124B2 (en) | Method for transesterification of fats and oils using immobilized lipase | |
JP2657887B2 (en) | Preparation method of immobilized enzyme | |
JP2676470B2 (en) | Immobilized lipase, method for producing the same, and method for transesterifying oils and fats using the lipase | |
JP2004222595A (en) | Method for producing diglyceride | |
JPH01174384A (en) | Method for immobilizing lipid hydrolase | |
JPH0528114B2 (en) | ||
JPH01153090A (en) | Immobilized enzyme and method for synthesizing ester using said enzyme | |
JPH05501497A (en) | Transesterification of phospholipids | |
JPH04258291A (en) | Immobilized enzyme and its production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |